SRRK
Scholar Rock Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$46.65
−4.83%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -26.6%
- EBIT
- -25.7%
- EPS
- -11.1%
- Free cash flow
- -14.8%
- Operating cash flow
- -15.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +3.1%
- EPS
- +7.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -55.5%
- EBIT
- -52.6%
- Net income
- -53.5%
- EPS
- -33.2%
- Free cash flow
- -49.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026